With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG’s launch-tracking series will examine how the perception and performance of Zinbryta have evolved in the year since its launch in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profilesbut, on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.
What you will learn in this content:
Methodology: ~75-100 U.S. neurologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten of these specialists participated in a 30-minute follow-up qualitative interview.
Key drugs: Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons
Key companies: Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche/Genentech
Related reports: Emerging Therapies: Ocrevus (Relapsing MS and PP-MS companion series), Emerging Therapies: Lemtrada